ISTH 0036

Drug Profile

ISTH 0036

Alternative Names: ISTH0036

Latest Information Update: 28 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isarna Therapeutics
  • Class Antiglaucomas; Antisense oligonucleotides
  • Mechanism of Action Transforming growth factor beta2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Scars
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Open-angle glaucoma

Most Recent Events

  • 28 May 2018 No recent reports of development identified for phase-I development in Open-angle-glaucoma in Germany (Intravitreous, Injection)
  • 01 Aug 2017 Isarna Therapeutics completes a phase I trial in Open angle glaucoma in Germany (NCT02406833)
  • 15 May 2017 Adverse events data from a phase I trial in Open angle glaucoma released by Isarna Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top